CHITOGENX ANNOUNCES EXECUTIVE LEADERSHIP CHANGES
MONTREAL, Feb. 28, 2024 /CNW/ - ChitogenX Inc. (CSE: CHGX) (OTCQB: CHNXF) ("ChitogenX" or the "Company"), a clinical-stage regenerative medicine company, today announced that Philippe Deschamps, Chief Executive Officer, has decided to step down as CEO for personal reasons and has resigned from the Board of directors, effective February 28, 2024. Mr. Pierre Laurin who currently serves as Chairman of the Board of directors, will act as interim CEO while the Board of directors reviews potential alternatives to fill the position permanently.
The Board of directors of the Company thanks Mr. Deschamps for his efforts and commitment over his tenure and wishes him the best in his future endeavors. Mr. Deschamps intends to support the Company during this period of transition.
ChitogenX Inc. is a clinical stage regenerative medicine company dedicated to the development of novel therapeutic tissue repair technologies to improve tissue healing. The Company is committed to the clinical development of its proprietary Chitosan Based Biopolymer technology platform, a proprietary muco-adhesive scaffold, specifically designed to be combined with therapeutics to improve tissue repair.
Other formulations are being developed to leverage the technology's performance characteristics such as tissue adhesion, pliability, and ability to deliver biologics or therapeutics to various tissues damaged by trauma or disease. Further information about ChitogenX is available on the Company's website at www.chitogenx.com and on SEDAR at www.sedar.com.
This news release may contain certain forward-looking statements regarding the Company's expectations for future events. Such expectations are based on certain assumptions that are founded on currently available information. If these assumptions prove incorrect, actual results may differ materially from those contemplated by the forward-looking statements contained in this press release. Factors that could cause actual results to differ include, amongst others, uncertainty as to the final result and other risks. The Company disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by security laws.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
SOURCE Ortho Regenerative Technologies Inc.
Contacts: Company: Pierre Laurin, Interim President and Chief Executive Officer, 514-475-2588, [email protected] or Luc Mainville, Senior Vice-president and Chief Financial Officer, 514-693-8854, [email protected]; Investors: Frederic Dumais, Director Communications and Investor Relations, (514) 261-4735, [email protected]
Share this article